Akums' Subsidiary Acquires Oriflame India Manufacturing Business, Valued at INR 56 Crore
Akums Drugs and Pharmaceuticals Limited is expanding its operational footprint into cosmetics after its wholly-owned subsidiary approved the acquisition of manufacturing assets from Oriflame India Private Limited. The transaction, finalized by the company's board on July 23, 2026, involves acquiring core production capabilities across multiple locations in India for a total consideration of INR 56 Crore.Pure and Cure Healthcare Private Limited, the subsidiary of Akums, will take over two manufacturing plants situated in Roorkee, Uttarakhand, and Noida, Uttar Pradesh. The acquisition package also includes a leased warehouse located in Noida.
This strategic move marks Akums' entry into the color cosmetics segment. The deal is set to significantly expand the company’s presence within both skincare and wellness products for markets across India and globally. The transaction specifically involves the manufacturing business of Oriflame India Private Limited, while the trademark and marketing rights for Oriflame’s products in India remain outside the scope of this acquisition.
The intended completion period for the acquisition has been set by the management team, with an estimated timeline concluding by August 31, 2026. The purchase involves a cash consideration payment.
Key details regarding the corporate development are summarized below:
| Aspect | Details |
|---|---|
| Acquiring Entity | Pure and Cure Healthcare Private Limited (Subsidiary of Akums) |
| Target Business | Manufacturing business of Oriflame India Private Limited |
| Total Consideration | INR 56 Crore |
| Assets Acquired | Two manufacturing plants (Roorkee, Uttarakhand; Noida, Uttar Pradesh) and a leased warehouse in Noida |
| Strategic Impact | Marks entry into color cosmetics and expansion in skincare & wellness products. |
| Projected Completion | August 31, 2026 |
AKUMS Stock Price Movement
Shares of Akums Drugs and Pharmaceuticals Limited shed value on Thursday, settling at ₹695.9 after a 0.62% decline. The stock traded within a range defined by a high of ₹701.1 and a low of ₹686.95 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.